Please login to the form below

Not currently logged in
Email:
Password:

TauRx

This page shows the latest TauRx news and features for those working in and with pharma, biotech and healthcare.

Another amyloid bust as Roche pulls crenezumab trials

Another amyloid bust as Roche pulls crenezumab trials

AD have also yielded disappointing results for companies including TauRx, Zeltia, Bristol-Myers Squibb and Allon/Paladin Labs.

Latest news

  • Lilly partners with AC Immune on tau drug for Alzheimer’s Lilly partners with AC Immune on tau drug for Alzheimer’s

    The company credited with pioneering the tau hypothesis in AD is TauRx, although its aggregation inhibitor LMTX disappointed in an 891-paient phase 3 trial reported in 2016.

  • AbbVie takes anti-tau drug into phase II for Alzheimer's AbbVie takes anti-tau drug into phase II for Alzheimer's

    Whether tau-targeting drugs can do better remains to be seen. Last year, TauRx's tau aggregation inhibitor LMTX failed to slow cognitive decline in three phase III trials - two in ... TauRx also said it had cognitive benefit in a subset of patients not

  • Tau protein drug fails late-stage trial Tau protein drug fails late-stage trial

    year. TauRx' tau aggregation inhibitor LMTX failed to meet its objective of improving cognition and the ability to carry out everyday tasks in the trial, which involved 891 patients with mild ... TauRx has two other trials in play – one in mild

  • AbbVie and C2N take tau antibody into clinic AbbVie and C2N take tau antibody into clinic

    Other companies working on tau as a target include TauRx Therapeutics, which has a phase III trial ongoing of its lead candidate LTX in Alzheimer's and is due to report

  • Alzheimer's disease pipeline takes multiple hits Alzheimer's disease pipeline takes multiple hits

    Of these, TRx 0237 (leuco-methylthioninium, TauRx Pharmaceuticals), an oral agent shown to inhibit tau aggregation, is in phase III trials in the US and the UK in patients with ... Two agents targeting tau have been discontinued recently at phase II –

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics